Ozempic and Zepbound are the two names most people know, so they're often compared directly. But they differ on two counts at once: the molecule inside and the condition each is approved to treat. That makes a straight comparison a bit like comparing a sedan from one carmaker with a truck from another. The grid below sorts the four big brands so you can see which pairs actually match.
Different molecules from different companies
Ozempic contains semaglutide, made by Novo Nordisk. It acts on one gut-hormone receptor, GLP-1. Zepbound contains tirzepatide, made by Eli Lilly. It acts on two, GIP and GLP-1. So Zepbound isn't a semaglutide, and it isn't a stronger version of Ozempic. It's a separate drug with its own trials. The semaglutide vs tirzepatide comparison covers what the two molecules did head to head.
Two molecules, two labels: the four brands on one grid
| Molecule | Type 2 diabetes label | Weight-management label |
|---|---|---|
| Semaglutide (Novo Nordisk) | Ozempic, approved December 2017 | Wegovy, approved June 2021 |
| Tirzepatide (Eli Lilly) | Mounjaro, approved May 2022 | Zepbound, approved November 2023 |
| Other approved uses | Ozempic: heart-risk reduction in type 2 diabetes with heart disease; kidney protection in type 2 diabetes with chronic kidney disease (2025). Mounjaro: heart-risk reduction in high-risk type 2 diabetes (2026); children 10 and older | Wegovy: heart-risk reduction with heart disease and obesity or overweight (2024); MASH liver disease (2025); teens 12 and older. Zepbound: sleep apnea with obesity (2024) |
Ozempic and Zepbound sit on opposite corners. Labels: Ozempic [4], Wegovy [6], Mounjaro [7], Zepbound [5].
Read across a row and you get the same drug for two jobs. Read down a column and you get two drugs for the same job. Ozempic and Zepbound share neither, which is why the honest answer to "which is better" usually starts with "for what?"
Which helps more with weight loss? Compare Zepbound with Wegovy instead
Ozempic isn't approved for weight loss, so no trial compared Ozempic with Zepbound for that use. The trial that answers the question compared Zepbound with Ozempic's weight-labeled twin, Wegovy. In SURMOUNT-5, people with obesity lost 20.2% of body weight on Zepbound and 13.7% on Wegovy over 72 weeks [1]. Lilly funded the trial.
There's also a diabetes-side clue. In SURPASS-2, people with type 2 diabetes lost 4.2 to 12.1 pounds (1.9 to 5.5 kg) more on tirzepatide than on semaglutide 1 mg, an Ozempic dose, over 40 weeks [2]. That trial measured blood sugar first, and Lilly funded it too. The Zepbound vs Wegovy comparison has the full weight picture.
If you have type 2 diabetes and obesity, here's what the labels say
Many people asking this question have both conditions. Both weight-management labels, Zepbound's and Wegovy's, cover adults with obesity or with overweight plus a weight-related condition, and both drugs were tested in people with type 2 diabetes. In SURMOUNT-2, adults with obesity and type 2 diabetes lost 12.8% and 14.7% of their weight at the two tirzepatide doses tested, against 3.2% on placebo [3]. That's less than people without diabetes lose on the same drug.
- Low blood sugar. Zepbound's label says it "lowers blood glucose and can cause hypoglycemia." In its diabetes trial, low blood sugar hit 10.3% of people also taking a sulfonylurea, against 2.1% of those who weren't [5]. Ozempic's label carries the same caution with insulin or sulfonylureas [4].
- Heart and kidney labels. Ozempic is labeled to cut heart-attack and stroke risk in type 2 diabetes with heart disease, and to slow kidney decline in type 2 diabetes with chronic kidney disease [4]. Zepbound has neither indication.
- Coverage. A diabetes diagnosis usually makes a diabetes label, Ozempic or Mounjaro, easier for a plan to cover. Weight-management drugs are excluded by many plans.
Which one fits is a call for you and your prescriber, and it often comes down to which of those three matters most to you. The Ozempic guide and Zepbound guide cover each drug's dosing and warnings in full.
Doses and devices differ, and the milligrams don't compare
Both are once-weekly injections, but that's where the overlap ends. The numbers on the box mean different things because the molecules differ, so 2 mg of Ozempic and 2.5 mg of Zepbound aren't "about the same dose."
| Ozempic | Zepbound | |
|---|---|---|
| Label starting dose | 0.25 mg once weekly | 2.5 mg once weekly |
| Label maximum | 2 mg once weekly | 15 mg once weekly |
| Devices | Multi-dose pens; single-dose prefilled syringes | Single-dose pens and vials; multi-dose vials; KwikPens |
| Pill sibling | Ozempic tablets (type 2 diabetes) | None |
Ozempic label [4]; Zepbound label [5]. Your prescriber sets the steps in between.
Ozempic also has a daily tablet sibling for type 2 diabetes, Ozempic tablets, which is a separate product from the Wegovy pill. Zepbound has no pill; Lilly's daily weight-loss tablet, Foundayo, is a different drug.
Side effects are similar, because they're the same drug class
Ozempic's most common side effects are nausea, vomiting, diarrhea, abdominal pain and constipation [4]. Zepbound's list is similar, plus indigestion, injection-site reactions, fatigue, burping, hair loss and reflux [5]. Both carry the same boxed warning about thyroid C-cell tumors seen in rodents, and both warn about pancreatitis, gallbladder disease and kidney injury from dehydration. Using either with another GLP-1 drug isn't recommended.
Cost without insurance: close at the lower doses
| Product and dose | Self-pay per month | Conditions |
|---|---|---|
| Ozempic 0.25 mg and 0.5 mg | $199 | New patients, first 2 fills, through December 31, 2026 |
| Ozempic 0.25 mg, 0.5 mg, 1 mg | $349 | Standard self-pay price; one pen per month |
| Ozempic 2 mg | $499 | Standard self-pay price |
| Zepbound 2.5 mg | $299 | Vial or KwikPen |
| Zepbound 5 mg | $399 | Vial or KwikPen |
| Zepbound 7.5 mg to 15 mg | $449 | Refill within 45 days; otherwise $499 to $699 |
NovoCare [8] and LillyDirect [9]. NovoCare says Ozempic pricing will be updated after December 31, 2026.
In money terms, a new Ozempic patient pays $398 for the first two months, then $349. A new Zepbound patient pays $299 at the starting dose and $399 at 5 mg. With commercial insurance that covers either drug, each maker offers a savings card that can bring the copay as low as $25. The Ozempic cost guide and Zepbound cost guide go deeper.